

Please amend the claims to read follows:

---

30. (Amended) An antibody or antibody fragment which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN).

31. (Amended) An antibody or antibody fragment according to claim 30, which comprises a mammalian antibody-antigen binding domain.

32. (Amended) An antibody or antibody fragment according to claim 31, wherein said antibody-antigen binding domain is of human origin.

33. (Amended) An antibody or antibody fragment according to claim 30, which binds to FN containing ED-B after treatment of the FN with the protease thermolysin.

F2 34. (Amended) An antibody or antibody fragment according to claim 30, which binds to recombinant FN containing type III homology repeats which include the ED-B domain.

35. (Amended) An antibody or antibody fragment according to claim 30, whose binding to B-FN is inhibited by the ED-B domain.

36. (Amended) An antibody or antibody fragment according to claim 30, which binds to B-FN from human, mouse, rat, chicken, and any other species in which the ED-B domain is conserved.

37. (Amended) An antibody or antibody fragment according to claim 30, which binds to B-FN without treatment of the FN with N-glycanase.

---

F3 38. (Twice Amended) An antibody or antibody fragment according to claim 30, having a variable heavy (VH) chain region of the sequence (aa 1 Glu – aa 98 Arg inclusive in

Figure 1) (SEQ ID NO: 9) and the CDR3 sequence Ser Leu Pro Lys (SEQ ID NO: 12).

F3  
39. (Twice Amended) An antibody or antibody fragment according to claim 30, having a variable heavy (VH) chain region of the sequence (aa 1 Glu – aa 98 Arg inclusive in Figure 1) (SEQ ID NO.: 9) and the CDR3 sequence Gly Val Gly Ala Phe Arg Pro Tyr Arg Lys His Glu (SEQ ID NO:1).

---

40. (Twice Amended) An antibody or antibody fragment according to claim 30, having a variable light (VL) chain region of the sequence (aa 1 Ser – aa 90 Ser inclusive in Figure 1) (SEQ ID NO.: 10) and the remainder of the CDR3 sequence as Pro Val Val Leu Asn Gly Val Val (SEQ ID NO: 13).

---

F4  
41. (Twice Amended) An antibody or antibody fragment according to claim 30, having a variable light (VL) chain region of the sequence (aa 1 Ser – aa 90 Ser inclusive in Figure 1) (SEQ ID NO.: 11) and the remainder of the CDR3 sequence as Pro Phe Glu His Asn Leu Val Val (SEQ ID NO: 14).

---

F5  
42. (Twice Amended) An antibody or antibody fragment according to claim 30, having a variable heavy (VH) chain region of the sequence (aa 1 Glu – aa 98 Arg inclusive in Figure 1) (SEQ ID NO.: 9) and the CDR3 sequence.

---

43. (Amended) An antibody or antibody fragment according to claim 30, which, when measured as a purified monomer, has a dissociation constant ( $K_d$ ) of about  $6 \times 10^{-8}M$  for ED-B FN.

---

F6  
44. (Amended) An antibody or antibody fragment according to claim 30, which comprises an scF<sub>v</sub> molecule.

45. (Amended) An antibody or antibody fragment according to claim 30, which